Anaplastic Thyroid Cancer Clinical Trials

35 clinical trials for Anaplastic Thyroid Cancer across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• XL092 and Cemiplimab in BRAF WT Thyroid Cancer — RECRUITING · PHASE1
• Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer — RECRUITING · PHASE2
• Sacituzumab govitEcan in THYroid Cancers — RECRUITING · PHASE2
• NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) — RECRUITING · PHASE2
• An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) — TERMINATED · PHASE2
• Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer — NOT_YET_RECRUITING · PHASE2
• Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial — NOT_YET_RECRUITING · PHASE1
• Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) — ACTIVE_NOT_RECRUITING · PHASE2
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study — COMPLETED · PHASE2
• Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer — COMPLETED · PHASE2
• Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors — TERMINATED · PHASE1
• Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• (NEOAC) NEO- and Adjuvant Targeted therapy in braf-mutated Anaplastic Cancer of the Thyroid - a prospective, non-randomized, single center, open-label phase II study. — TERMINATED · PHASE2
• Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer — COMPLETED · PHASE2
• Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy — OTHER · PHASE2
• A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer — COMPLETED · PHASE1
• The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation — OTHER · PHASE1
• Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences — OTHER
• European Multicenter Study on Surgical Management of Advanced Thyroid Cancer — OTHER
• Phase I/II Study of PDR001 in Patients With Advanced Malignancies — COMPLETED · PHASE1
• Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer — COMPLETED · PHASE2
• interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT) — OTHER
• Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) — OTHER · PHASE2
• A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel — TERMINATED · PHASE1
• Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer — COMPLETED · PHASE2
• Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer — TERMINATED · PHASE2
• A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) — COMPLETED · PHASE1
• Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer — TERMINATED · PHASE2
• Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer — WITHDRAWN · PHASE3
• Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer — TERMINATED · PHASE2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu — COMPLETED · PHASE1
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer — COMPLETED · NA
• Review of Multimodality Management of Anaplastic Thyroid Cancer — COMPLETED

Refine this search